Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Operating Results by Reportable Segment (Detail)

v3.8.0.1
Segment Information - Operating Results by Reportable Segment (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Segment Reporting Information [Line Items]      
Net Revenue $ 55,425 $ 44,682  
Direct cost of goods (1,472) (469)  
Sales and marketing costs (2,764) (2,267)  
Research and development (25,055) (8,404)  
General and administrative (10,784) (7,985)  
National Expenses 90,911 62,259  
Segment income (loss) from operations (35,486) (17,577)  
Segment assets 265,075   $ 245,950
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 5,509 2,085  
Direct cost of goods (1,472) (469)  
Sales and marketing costs (2,764) (2,267)  
Research and development 0 0  
General and administrative (397) (319)  
National Expenses 0 0  
Segment income (loss) from operations 876 (970)  
Segment assets 11,163 4,039  
Pharmaceutical And Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 394 693  
Direct cost of goods 0 0  
Sales and marketing costs 0 0  
Research and development (25,055) (8,404)  
General and administrative (10,387) (7,666)  
National Expenses 0 0  
Segment income (loss) from operations (35,048) (15,377)  
Segment assets 189,560 159,175  
National [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 49,522 41,904  
Direct cost of goods 0 0  
Sales and marketing costs 0 0  
Research and development 0 0  
General and administrative 0 0  
National Expenses (50,836) (43,134)  
Segment income (loss) from operations (1,314) (1,230)  
Segment assets 64,352 48,697  
Consolidated [Member]      
Segment Reporting Information [Line Items]      
National Expenses   (43,134)  
Segment assets $ 265,075 $ 211,911